OBSOLETE: Peeling skin syndrome type C

Peeling skin syndrome type C (also known as peeling skin syndrome, inflammatory type or peeling skin disease type C) was a clinical subtype designation within the peeling skin syndromes, a group of rare inherited skin disorders characterized by painless, spontaneous superficial peeling (exfoliation) of the skin. This particular subtype was distinguished by generalized peeling of the skin accompanied by significant inflammatory features, including widespread redness (erythroderma), pruritus (itching), and sometimes associated atopic manifestations such as elevated IgE levels, food allergies, and asthma. The skin barrier dysfunction leads to recurrent superficial shedding of the outermost layer of the epidermis (stratum corneum), which can be present from birth or early infancy. This Orphanet entry (ORPHA:263558) is now classified as OBSOLETE, meaning the designation 'peeling skin syndrome type C' is no longer considered a distinct clinical entity in current nosology. The condition has been reclassified and merged into the broader category of peeling skin syndrome or more specifically into SAM syndrome (severe dermatitis, multiple allergies, and metabolic wasting) or other molecularly defined peeling skin disorders, depending on the underlying genetic cause. Mutations in genes such as CDSN (corneodesmosin) and TGM5 (transglutaminase 5) have been associated with various forms of peeling skin syndrome, while the inflammatory type has been linked to mutations in CDSN or other desmosomal genes. Treatment remains symptomatic and supportive, including emollients to maintain skin hydration, topical anti-inflammatory agents, and management of allergic and atopic complications. No curative therapy currently exists for any form of peeling skin syndrome.

Common questions about OBSOLETE: Peeling skin syndrome type C